NO324074B1 - Anvendelse av 4-substituerte tetrahydropyridiner for fremstilling av farmasoytiske preparater som virker pa TGF-<beta>1, samt en forbindelse - Google Patents

Anvendelse av 4-substituerte tetrahydropyridiner for fremstilling av farmasoytiske preparater som virker pa TGF-<beta>1, samt en forbindelse Download PDF

Info

Publication number
NO324074B1
NO324074B1 NO19995821A NO995821A NO324074B1 NO 324074 B1 NO324074 B1 NO 324074B1 NO 19995821 A NO19995821 A NO 19995821A NO 995821 A NO995821 A NO 995821A NO 324074 B1 NO324074 B1 NO 324074B1
Authority
NO
Norway
Prior art keywords
tetrahydropyridine
ethyl
group
trifluoromethylphenyl
alkyl
Prior art date
Application number
NO19995821A
Other languages
English (en)
Norwegian (no)
Other versions
NO995821L (no
NO995821D0 (no
Inventor
Umberto Guzzi
Jean-Marc Herbert
Francoise Bono
Isabelle Lamarche
Jacqueline Fournier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO995821D0 publication Critical patent/NO995821D0/no
Publication of NO995821L publication Critical patent/NO995821L/no
Publication of NO324074B1 publication Critical patent/NO324074B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19995821A 1997-05-28 1999-11-26 Anvendelse av 4-substituerte tetrahydropyridiner for fremstilling av farmasoytiske preparater som virker pa TGF-<beta>1, samt en forbindelse NO324074B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9706522A FR2763847B1 (fr) 1997-05-28 1997-05-28 Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
PCT/FR1998/001000 WO1998053821A1 (fr) 1997-05-28 1998-05-20 Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta1

Publications (3)

Publication Number Publication Date
NO995821D0 NO995821D0 (no) 1999-11-26
NO995821L NO995821L (no) 2000-01-28
NO324074B1 true NO324074B1 (no) 2007-08-06

Family

ID=9507317

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19995821A NO324074B1 (no) 1997-05-28 1999-11-26 Anvendelse av 4-substituerte tetrahydropyridiner for fremstilling av farmasoytiske preparater som virker pa TGF-<beta>1, samt en forbindelse

Country Status (16)

Country Link
US (3) US6342505B1 (ja)
EP (1) EP1017385B1 (ja)
JP (1) JP2002511855A (ja)
AR (1) AR012856A1 (ja)
AT (1) ATE245027T1 (ja)
AU (1) AU7774898A (ja)
BR (1) BR9809444A (ja)
CA (1) CA2290557C (ja)
DE (1) DE69816456T2 (ja)
DK (1) DK1017385T3 (ja)
ES (1) ES2201502T3 (ja)
FR (1) FR2763847B1 (ja)
NO (1) NO324074B1 (ja)
PT (1) PT1017385E (ja)
WO (1) WO1998053821A1 (ja)
ZA (1) ZA984564B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757510B1 (fr) * 1996-12-23 2000-01-07 Sanofi Sa Forme microparticulaire d'un derive de tetrahydropyridine
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1
FR2831166B1 (fr) * 2001-10-18 2004-02-27 Sanofi Synthelabo Aralkyl-tetrahydro-pyridines, leur preparation et compositions pharmaceutiques les contenant
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US20090076048A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched xaliproden
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2531707A1 (fr) 1982-08-16 1984-02-17 Midy Spa Trifluoromethylphenyltetrahydropyridines substituees a activite anorexigene, un procede de preparation et compositions pharmaceutiques
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2662442A1 (fr) 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
US5618822A (en) 1990-05-23 1997-04-08 Sanofi N-substituted trifluoromethylphenyltetrahydropyridines, process for the preparation thereof, intermediates in said process and pharmaceutical compositions containing them
FR2672213B1 (fr) 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
HU211019B (en) 1991-12-02 1995-09-28 Richter Gedeon Vegyeszet Process for producing new 1,2,3,6-tetrahydropyridine and piperidine derivatives substituted with n-(hydroxylalkyl) group and compositions comprising such compounds
US5522011A (en) * 1993-09-27 1996-05-28 International Business Machines Corporation Speech coding apparatus and method using classification rules
MX9603868A (es) 1995-01-11 1997-03-29 Otsuka Pharma Co Ltd Composicion farmaceutica de derivados de indeno para la regulacion de la apoptosis.
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
FR2757161B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa Diphenylalkyl-tetrahydropyridines
FR2762514B1 (fr) * 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
FR2763847B1 (fr) * 1997-05-28 2003-06-06 Sanofi Sa Utilisation de tetrahydropyridines 4-substituees pour fabriquer des medicaments agissant sur le tgf-beta-1

Also Published As

Publication number Publication date
PT1017385E (pt) 2003-10-31
WO1998053821A1 (fr) 1998-12-03
DE69816456T2 (de) 2004-04-15
FR2763847A1 (fr) 1998-12-04
NO995821L (no) 2000-01-28
NO995821D0 (no) 1999-11-26
US20040157868A1 (en) 2004-08-12
JP2002511855A (ja) 2002-04-16
EP1017385B1 (fr) 2003-07-16
ATE245027T1 (de) 2003-08-15
CA2290557A1 (en) 1998-12-03
US6342505B1 (en) 2002-01-29
CA2290557C (en) 2007-11-27
FR2763847B1 (fr) 2003-06-06
EP1017385A1 (fr) 2000-07-12
ES2201502T3 (es) 2004-03-16
BR9809444A (pt) 2000-06-13
US20020091143A1 (en) 2002-07-11
ZA984564B (en) 1998-12-03
AR012856A1 (es) 2000-11-22
DK1017385T3 (da) 2003-10-27
AU7774898A (en) 1998-12-30
US7320982B2 (en) 2008-01-22
US6693118B2 (en) 2004-02-17
DE69816456D1 (de) 2003-08-21

Similar Documents

Publication Publication Date Title
JP5461405B2 (ja) 嚢胞性線維症膜コンダクタンス制御因子の調節因子
CN105683157B (zh) 用作钠通道调节剂的磺酰胺类
EP2951168B1 (en) Quinoline and quinoxaline amides as modulators of sodium channels
CN105814067B (zh) 作为钠通道调节剂的吡啶酮酰胺的前药
CN105254557A (zh) 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物
US20070299122A1 (en) Method of Treating Pathological Blushing
JP3956059B2 (ja) 髄鞘破壊を引き起こす疾患を治療するための医薬製造へのテトラヒドロピリジン誘導体の使用
CN104968647A (zh) 作为钠通道调节剂的酰胺
EP0996443A1 (en) Certain diarylimidazole derivatives; a new class of npy specific ligands
CN103391932B (zh) 用于抑制pask的杂环化合物
WO1996004914A1 (fr) Derive de triazine et medicament
KR20240031299A (ko) (2r,3s,4s,5r)-4-[[3-(3,4-디플루오로-2-메톡시-페닐)-4,5-디메틸-5-(트리플루오로메틸)테트라하이드로푸란-2-카르보닐]아미노]피리딘-2-카르복사미드를 포함하는 고체 투여 형태 및 투여 요법
NO324074B1 (no) Anvendelse av 4-substituerte tetrahydropyridiner for fremstilling av farmasoytiske preparater som virker pa TGF-&lt;beta&gt;1, samt en forbindelse
WO2022192731A1 (en) Compositions and methods for treating anemia associated with a ribosomal disorder
EP0773019A1 (en) Hyperlipemia remedy
TW474918B (en) Substituted oximes as neurokinin antagonists
MXPA99010961A (en) Use of 4-substituted tetrahydropyridines for making medicines acting on tgf-&amp;bgr;1
KR20200006128A (ko) 나트륨 채널의 조절제로서의 중수소화 피리돈 아미드 및 이의 프로드럭
CZ474699A3 (cs) Určité diarylimidazolové deriváty a kompozice obsahující tyto deriváty, které se selektivně vážou na humánní NPY receptory